Načítá se...
Sorafenib Improves Survival in Metastatic Hepatocellular Carcinoma: A Case Report
Hepatocellular carcinoma (HCC) is a very common cancer. Curative treatments and local ones are well validated. Sorafenib, a multi-kinase receptor inhibitor was introduced in 2007 for advanced HCC in patients with preserved liver function. HCC is known to be resistant to systemic chemotherapy, and th...
Uloženo v:
| Vydáno v: | World J Oncol |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Elmer Press
2010
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5649801/ https://ncbi.nlm.nih.gov/pubmed/29147210 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4021/wjon240w |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|